News

Molecules needed for energy production in cells apparently underwent a radical change during early animal evolution so they could continue to function despite a relatively high mutation rate.

The discovery of an insulin “decoy” molecule from the lab of Matthew Gill, PhD, in Florida shakes up understanding of insulin signaling, with implications for diabetes, longevity and aging research.  

A team at Scripps Research in Florida has developed a mouse model of a known cause of autism spectrum disorder, a mutation in the gene PTEN, that leads the brain to develop to an abnormal scale, with autism-like behaviors resulting. Restoring one of PTEN’s key activities in that mouse model led to a reversal of some cell overgrowth, offering a potential therapeutic target.   

In a study with implications for the future of drug discovery, Scripps Research scientists showed they were able to turn simple chemicals into unique 3-D structures resembling those found in nature.

The rating acknowledges nonprofit organizations and charities that exceed industry standards in financial health, accountability and transparency.

In a heart study of unprecedented scale, researchers evaluated the resting heart rate of more than 92,000 individuals for over 32 million days using de-identified data from fitness-tracking devices.

Having achieved this regulatory milestone, Calibr can begin clinical trials for its novel cell therapy candidate, which leverages a patient's own immune cells to treat cancer.

Renewed support from the Bill & Melinda Gates Foundation to accelerate research by Calibr, the drug development division of Scripps Research.

The clinical-stage biopharmaceutical company BlackThorn Therapeutics, a spin-off from Scripps Research, has begun patient enrollment for a phase 2 clinical trial to evaluate the impact of its lead drug candidate in individuals with major depressive disorder.

A professor and associate dean, Havran pursued groundbreaking immunology research that revealed key mechanisms of wound healing.

An abundance of microRNA-21 predicts lower survival in people with hard-to-treat “triple-negative” breast cancer. An innovative compound from Disney Lab awakened those cancer cells’ self-destruct system, killing the cancer cells and stopping their spread in a mouse model, while leaving healthy cells untouched.

Alda, the Emmy Award-winning actor, director and writer who has become a leading advocate for effective science communication, has partnered with Scripps Research to bring immersive communication training to scientists.

By analyzing millions of data points from wearable devices, Scripps Research scientists were able to significantly improve statewide predictions of flu epidemics.

Under a two-year contract and funding agreement, Calibr will screen its vast library of drug molecules for compounds that work against a rare but vexing family of bacteria.

Why do we remember some things for our entire lives but quickly forget others? The brain is constantly deciding which events are important enough for long-term storage.  A new study from the lab of neuroscientist Ron Davis, PhD, sheds light on one element of that process.

Mitochondrial damage is increasingly recognized as a major factor for neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and ALS. A new screening platform has identified a set of drug-like compounds that may powerfully protect mitochondria.

A drug-like compound is able to selectively prevent production of the protein underlying most causes of Parkinson’s disease, alpha-synuclein.

Chemists’ discovery of a small bacterial molecule with natural and ‘inside-out’ versions could have implications for future drug development

Scientists at Scripps Research have developed a special molecular switch that could be embedded into gene therapies to allow doctors to control dosing.

Scientists report for the first time that cerebral organoids created with cells from Alzheimer’s patients manifest excessive electrical activity just like people who have the disease.

Chemists at Scripps Research have found a new and easy route for creating an enormous variety of organic molecules for use as potential drugs or other chemical products.

A collaboration to develop new therapies for a range of diseases, including oncology, immunology, neurology and fibrosis, is announced with the goal to advance novel medicines to patients.

Topol was honored for his contributions in genomic and digital technologies to transform the practice of medicine.